Novartis

2024 ended on a strong note; 2025 outlook surpassed expectations

05/02/25 -"The Q4 earnings were ahead of consensus estimates, driven by a robust showing across key focus areas. Moreover, the 2025 outlook was better than the street’s expectations. While we expect ..."

PDF page sample
Pages
65
Language
English
Published on
05/02/25
Download
You may also be interested by these reports :
06/11/25
The Q3 results surpassed expectations, backed by strong performance from Oncology, Respiratory & Immunology, and Rare Disease medicines. Now, the ...
06/11/25
The Q3 profits were ahead of consensus and, consequently, the management upgraded its 2025 guidance at February 2025 FX rates. However, FX headwinds ...
05/11/25
The Q3 results missed expectations, as Novo contended with competition from compounding pharmacies and Eli Lilly. Moreover, the management again ...
04/11/25
The Q3 operating profitability exceeded expectations, though sales fell short of consensus. The management reaffirmed its full-year guidance. While ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO